AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6837235 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 30
Study 6837235 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 30
Study 6837235 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural analgesia
Number of subjects: 30
Study 6837235 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 31153127 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual actions performed by a model using her head or sitting on the apparatus (hands-occupied condition)
Number of subjects: 293
Study 31153127 — intervention group
Group type: EXPERIMENTAL
Intervention: Unusual actions performed by a model using her hands (hands-free condition)
Number of subjects: 293
Study 31153127 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze behavior directed at the model after reenacting the observed action
Number of subjects: 293
Study 29946818 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration (CA) of intravenous iron: 100 mg sucrose iron agents during every HD session, total dose of 1000 mg.
Number of subjects: 41
Study 29946818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration (IA) of intravenous iron: 100 mg sucrose iron agents once every week, total dose of 1000 mg.
Number of subjects: 41
Study 29946818 — intervention group
Group type: COMPARATOR
Intervention: Both CA and IA
Number of subjects: 41
Study 27090417 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) training for 6 weeks
Number of subjects: 35
Study 27090417 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 35
Study 24664093 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor Office Collaborative Care (DOCC)
Number of subjects: 321
Study 24664093 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 321
Study 22972443 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (7 dietary counseling calls)
Number of subjects: 87
Study 22972443 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention (7 one-to-one dietary counseling sessions)
Number of subjects: 87
Study 22972443 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no additional contact)
Number of subjects: 87
Study 21199119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% sevoflurane
Number of subjects: 96
Study 21199119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% sevoflurane
Number of subjects: 96
Study 21199119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% sevoflurane
Number of subjects: 96
Study 17657963 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutoxim, 60 mg/day for 52 days
Number of subjects: 118
Study 17657963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 118
Study 15768874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbs
Number of subjects: 0
Study 15768874 — intervention group
Group type: COMPARATOR
Intervention: Randomized control trial
Number of subjects: 0
Study 12357714 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide (IB) 0.6% nasal spray
Number of subjects: 22
Study 12357714 — intervention group
Group type: COMPARATOR
Intervention: vehicle (placebo)
Number of subjects: 22
Study 10828701 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction assay
Number of subjects: 100
Study 9190003 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 40 mg of prednisone
Number of subjects: 17
Study 8476830 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 200
Study 8476830 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 200
Study 3081622 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperventilation to maintain PaCO2 between 3.5 and 5 kPa
Number of subjects: 20
Study 3081622 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation only if severe hypoxia or hypercapnia occurred (Control)
Number of subjects: 20
Study 29277553 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydration (EUH) - drinking 2500ml/24h
Number of subjects: 12
Study 29277553 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - monitoring food and fluid intake
Number of subjects: 12
Study 29277553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration (DEH) - minimizing drinking
Number of subjects: 12
Study 27487479 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 99
Study 27487479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24470281 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-FFA 2 g daily
Number of subjects: 88
Study 24470281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 24354714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryotherapy
Number of subjects: 176
Study 24354714 — intervention group
Group type: COMPARATOR
Intervention: Excision and corticosteroids
Number of subjects: 176
Study 24354714 — intervention group
Group type: COMPARATOR
Intervention: Excision and brachytherapy
Number of subjects: 176
Study 20226475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral cardiac denervation in addition to coronary artery bypass grafting
Number of subjects: 220
Study 20226475 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting only (Control)
Number of subjects: 220
Study 18688562 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (GG)
Number of subjects: 76
Study 18688562 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (TT)
Number of subjects: 76
Study 16651509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (n = 79)
Number of subjects: 152
Study 16651509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 73)
Number of subjects: 152
Study 14717039 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief information and occlusal appliance
Number of subjects: 864
Study 14717039 — intervention group
Group type: COMPARATOR
Intervention: Brief information only
Number of subjects: 864
Study 14717039 — intervention group
Group type: COMPARATOR
Intervention: Brief information and relaxation therapy
Number of subjects: 864
Study 10815366 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support system (CDSS)
Number of subjects: 1034
Study 10815366 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1034
Study 8784075 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of recombinant human GH (0.03 mg/kg, sc)
Number of subjects: 8
Study 8784075 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of recombinant human GH (0.03 mg/kg, sc, 3 x /week)
Number of subjects: 8
Study 8784075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1624721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine plus magnesium gluconate
Number of subjects: 107
Study 1624721 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine alone
Number of subjects: 107
Study 31705219 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid switch from prednisone to dexamethasone
Number of subjects: 0
Study 31705219 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 0
Study 29627721 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (strategies against stigma and discrimination, psycho-education, social skills training, cognitive behavioral therapy)
Number of subjects: 327
Study 29627721 — intervention group
Group type: COMPARATOR
Intervention: Face to face interview (control group)
Number of subjects: 327
Study 26866731 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention for handoff communication skills
Number of subjects: 0
Study 25010430 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (CBT) and voucher-based reinforcement therapy (VBRT)
Number of subjects: 59
Study 25010430 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) with attendance-based reward program
Number of subjects: 59
Study 22158090 — intervention group
Group type: EXPERIMENTAL
Intervention: Trekking boots (TBs) on level natural terrain at several speeds (0.28, 0.56, 0.84, 1.11, and 1.39 m·s(‐1))
Number of subjects: 14
Study 22158090 — intervention group
Group type: COMPARATOR
Intervention: Treadmill at various raising slopes (0, 1, 2, 3, 4%) while wearing running shoes
Number of subjects: 14
Study 20863381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day (n = 42)
Number of subjects: 88
Study 20863381 — intervention group
Group type: COMPARATOR
Intervention: Increase in dose of other oral agents (n = 39)
Number of subjects: 88
Study 18547272 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 317
Study 16169327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/d)
Number of subjects: 36
Study 16169327 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate (40 mg/d)
Number of subjects: 36
Study 14750461 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CA125 group
Number of subjects: 771
Study 10329041 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal CA125 levels)
Number of subjects: 771
Study 10329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated CA125 group (excluding preexisting morbid conditions)
Number of subjects: 771
Study 8904586 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (n = 14)
Number of subjects: 42
Study 8904586 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training (n = 14)
Number of subjects: 42
Study 8904586 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (n = 14)
Number of subjects: 42
Study 1906905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 or 0.8 mg of nitroglycerin
Number of subjects: 23
Study 1906905 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg of cocaine
Number of subjects: 23
Study 1906905 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline solution
Number of subjects: 23
Study 1906905 — intervention group
Group type: COMPARATOR
Intervention: Sublingual placebo
Number of subjects: 23
Study 6652641 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom duration prior to treatment in patients with slower-growing tumors
Number of subjects: 160
Study 6652641 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom duration prior to treatment in patients with faster-growing tumors
Number of subjects: 160
Study 6652641 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer control activities to decrease the interval from recognition of symptoms to diagnosis and treatment
Number of subjects: 160
Study 6652641 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnosis and treatment during the symptomatic period for patients with faster-growing tumors
Number of subjects: 160
Study 6652641 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of asymptomatic cancer for patients with faster-growing tumors
Number of subjects: 160
Study 31278224 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K (n=41)
Number of subjects: 80
Study 31278224 — intervention group
Group type: COMPARATOR
Intervention: No vitamin K (n=39)
Number of subjects: 80
Study 29574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 mg/d) plus trifluoperazine (5 mg/d)
Number of subjects: 94
Study 29574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d) alone
Number of subjects: 94
Study 29574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change at week 2
Number of subjects: 94
Study 29574355 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain at week 6
Number of subjects: 94
Study 26908914 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (0.8 pmol/kg/min)
Number of subjects: 24
Study 26908914 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 24634003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day, 4 weeks on/2 weeks off)
Number of subjects: 735
Study 24634003 — intervention group
Group type: COMPARATOR
Intervention: Interferon α (9 MU subcutaneously 3 times per week)
Number of subjects: 735
Study 24634003 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 735
Study 22360330 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined actives (Furcellaria lumbricalis, Fucus vesiculosus, retinoid, conjugated linoleic acid, glaucine mixture)
Number of subjects: 0
Study 22360330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucus vesiculosus and Furcellaria lumbricalis
Number of subjects: 0
Study 22360330 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0
Study 22360330 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucine mixture
Number of subjects: 0
Study 22360330 — intervention group
Group type: COMPARATOR
Intervention: Combined actives
Number of subjects: 0
Study 20585005 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.25 g/kg/dose)
Number of subjects: 10
Study 20585005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16482098 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 22
Study 16482098 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 22
Study 12950959 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD)
Number of subjects: 11
Study 12950959 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients with ESLD)
Number of subjects: 11
Study 12950959 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 11
Study 10712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV)
Number of subjects: 61
Study 10712326 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 61
Study 10712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for hypoxemic ARF
Number of subjects: 61
Study 10712326 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC) for hypoxemic ARF
Number of subjects: 61
Study 10712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for hypercapnic ARF
Number of subjects: 61
Study 10712326 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC) for hypercapnic ARF
Number of subjects: 61
Study 10712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for non-COPD ARF
Number of subjects: 61
Study 10712326 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC) for non-COPD ARF
Number of subjects: 61
Study 10712326 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) for COPD
Number of subjects: 61
Study 10712326 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC) for COPD
Number of subjects: 61
Study 8998115 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant interferon-alpha-2b (IFN-alpha-2b)
Number of subjects: 0
Study 8998115 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective lymph node dissection (ELND)
Number of subjects: 0
Study 8998115 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 0
Study 1547301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium discontinuation
Number of subjects: 10
Study 1547301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3903785 — intervention group
Group type: EXPERIMENTAL
Intervention: Triletide (1.5 g/day)
Number of subjects: 20
Study 3903785 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone (0.3 g/day)
Number of subjects: 20
Study 31640312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic stretching (CS) program, 2 min of CS of the plantar flexor muscles, 5 times a week for 4 weeks
Number of subjects: 18
Study 31640312 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 30819356 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CTA)
Number of subjects: 1908
Study 30819356 — intervention group
Group type: COMPARATOR
Intervention: Functional stress testing
Number of subjects: 1908
Study 27856714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 15 l/min
Number of subjects: 13
Study 27856714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 l/min
Number of subjects: 13
Study 27856714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 45 l/min
Number of subjects: 13
Study 27856714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF)
Number of subjects: 13
Study 25733675 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal analysis
Number of subjects: 10000
Study 25733675 — intervention group
Group type: COMPARATOR
Intervention: Intent-to-treat analysis
Number of subjects: 10000
Study 23460810 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoke Pill
Number of subjects: 800
Study 23460810 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 800
Study 23113085 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the Broken Hill Proprietary (BHP) steel industry
Number of subjects: 0
Study 18950663 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit learning of a sequence
Number of subjects: 0
Study 18950663 — intervention group
Group type: COMPARATOR
Intervention: Procedural sequence learning
Number of subjects: 0
Study 17076840 — intervention group
Group type: EXPERIMENTAL
Intervention: InDel-based assay panel
Number of subjects: 73
Study 15214204 — intervention group
Group type: EXPERIMENTAL
Intervention: Renovated environment with a new dementia care unit and decentralized dining areas
Number of subjects: 0
Study 15214204 — intervention group
Group type: EXPERIMENTAL
Intervention: Renovated environment
Number of subjects: 0
Study 15214204 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized neighborhood design
Number of subjects: 0
Study 11990832 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) therapy
Number of subjects: 0
Study 9647030 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestid Granules
Number of subjects: 19
Study 9647030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8122598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG)
Number of subjects: 39
Study 8122598 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 39
Study 2527531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg oral dose)
Number of subjects: 12
Study 2527531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazaprilat (equivalent oral and intravenous doses)
Number of subjects: 12
Study 2527531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazaprilat (oral)
Number of subjects: 12
Study 2527531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (oral)
Number of subjects: 12
Study 1071709 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypertension and renal impairment in pregnancy (pre-eclampsia)
Number of subjects: 0
Study 1071709 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated essential hypertension in pregnancy
Number of subjects: 0
Study 30672254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fan-needle radiofrequency guided by meridians-muscles theory, treated at tendon nodes around knee joints (ashi points), 4 points per treatment, once every two weeks for 2 treatments.
Number of subjects: 100
Study 30672254 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of celecoxib capsules, 1 capsule every day for 4 weeks.
Number of subjects: 100
Study 29131826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive sports video game (IVG; Nintendo Wii™ Sports Resort)
Number of subjects: 8
Study 25457473 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin/metformin (50/1000 mg twice daily) SPC
Number of subjects: 99
Study 25457473 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin/metformin (50/1000 mg twice daily) SPC
Number of subjects: 99
Study 24284855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain exposure (VAS or VRS score > 0)
Number of subjects: 151
Study 24284855 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 151
Study 24284855 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 151
Study 21884601 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 4209
Study 18658043 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/d
Number of subjects: 39
Study 18658043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17035949 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day for 1 year)
Number of subjects: 83
Study 17035949 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin‐converting enzyme inhibitors and/or angiotensin type 1 receptor antagonists alone
Number of subjects: 83
Study 14604448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 169
Study 14604448 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 169
Study 11258635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue Lifting System (RLS)
Number of subjects: 14
Study 11258635 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques (Lifesling and navy rescue system)
Number of subjects: 14
Study 9205627 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 24
Study 9205627 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 24
Study 7966668 — intervention group
Group type: EXPERIMENTAL
Intervention: Isothermic transurethral prostatectomy (warmed irrigant at 38C)
Number of subjects: 52